Imagion Biosystems Limited (Company) is committed to ensuring that public confidence is maintained in the Company, its people and the trading of its securities. This policy sets out the company’s trading policy on buying and selling securities of the Company including shares, options, derivatives, managed investment products, superannuation products and any other financial products of the Company that are able to be traded on a financial market (Company’s Securities).
View the Imagion Biosystems Limited Securities Trading Policy.
Quarterly Activity Report – Quarter ending 31 December 2023
January 31, 2024
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal